Vigil Neuroscience (VIGL)
(Real Time Quote from BATS)
$3.35 USD
+0.11 (3.40%)
Updated Aug 8, 2024 11:18 AM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Cash flow Statements
Fiscal Year End for Vigil Neuroscience, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -82.64 | -68.31 | -43.28 | -28.55 | NA |
Depreciation/Amortization & Depletion | -1.08 | 0.08 | 0.03 | 0.00 | NA |
Net Change from Assets/Liabilities | 3.10 | -3.33 | 0.64 | 0.85 | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Operating Activities | 10.26 | 6.41 | 3.27 | 22.52 | NA |
Net Cash From Operating Activities | -70.36 | -65.15 | -39.35 | -5.18 | NA |
Property & Equipment | -0.67 | -0.92 | -0.20 | 0.00 | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Investments | -64.46 | 0.00 | 0.00 | 0.00 | NA |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Cash from Investing Activities | -65.14 | -0.92 | -0.20 | -0.50 | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.91 | 161.30 | 109.67 | 24.83 | NA |
Issuance (Repayment) of Debt | -0.02 | -0.04 | -0.04 | 0.00 | NA |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Financing Activities | 0.00 | 0.00 | -1.89 | 4.50 | NA |
Net Cash from Financing Activities | 0.89 | 161.26 | 107.75 | 29.83 | NA |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Change In Cash & Equivalents | -134.61 | 95.19 | 68.20 | 24.15 | NA |
Cash at Beginning of Period | 187.53 | 92.35 | 24.15 | 0.00 | NA |
Cash at End of Period | 52.92 | 187.53 | 92.35 | 24.15 | NA |
Diluted Net EPS | -2.13 | -2.16 | -28.26 | NA | NA |
Fiscal Year End for Vigil Neuroscience, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -19.94 | -82.64 | -60.46 | -39.97 |
Depreciation/Amortization & Depletion | NA | -0.31 | -1.08 | -1.49 | -0.82 |
Net Change from Assets/Liabilities | NA | -4.29 | 3.10 | -0.34 | -1.42 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 2.66 | 10.26 | 7.44 | 4.67 |
Net Cash From Operating Activities | NA | -21.88 | -70.36 | -54.85 | -37.54 |
Property & Equipment | NA | 0.00 | -0.67 | -0.66 | -0.61 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 16.47 | -64.46 | -75.13 | -90.49 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 16.47 | -65.14 | -75.79 | -91.11 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 5.18 | 0.91 | 0.86 | 0.80 |
Issuance (Repayment) of Debt | NA | 0.00 | -0.02 | -0.02 | -0.02 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 5.18 | 0.89 | 0.84 | 0.78 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -0.23 | -134.61 | -129.81 | -127.86 |
Cash at Beginning of Period | NA | 52.92 | 187.53 | 187.53 | 187.53 |
Cash at End of Period | NA | 52.69 | 52.92 | 57.72 | 59.67 |
Diluted Net EPS | NA | -0.50 | -0.57 | -0.53 | -0.52 |